Skip to main content

Invesco Dynamic Pharmaceuticals ETF (PJP)

NYSEARCA: PJP · IEX Real-Time Price · USD
78.66 0.07 (0.09%)
Oct 25, 2021 4:00 PM EDT - Market closed
Assets$430.22M
NAV$78.65
Expense Ratio0.56%
PE Ratio12.63
Shares Out5.47M
Dividend (ttm)$0.61
Dividend Yield0.77%
Ex-Dividend DateSep 20, 2021
1-Year Return
-
Volume7,799
Open78.59
Previous Close78.59
Day's Range78.10 - 78.76
52-Week Low60.95
52-Week High83.05
Beta0.85
Holdings24
Inception DateJun 23, 2005

About PJP

The investment seeks to track the investment results (before fees and expenses) of the Dynamic Pharmaceutical IntellidexSM Index. The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of common stocks of U.S. pharmaceutical companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.

Asset ClassEquity
SectorBiotech
RegionNorth America
IssuerInvesco
Stock ExchangeNYSEARCA
Ticker SymbolPJP
Index TrackedDynamic Pharmaceutical Intellidex Index

Top 10 Holdings

56.22% of assets
NameSymbolWeight
MerckMRK6.49%
Abbott LaboratoriesABT6.27%
Johnson & JohnsonJNJ5.80%
AmgenAMGN5.79%
Gilead SciencesGILD5.78%
Eli LillyLLY5.76%
AbbVieABBV5.66%
PfizerPFE5.54%
Supernus PharmaceuticalsSUPN4.58%
Ligand PharmaceuticalsLGND4.55%
View More Holdings

Dividends

Ex-DividendAmountPay Date
Sep 20, 2021$0.175Sep 30, 2021
Jun 21, 2021$0.14784Jun 30, 2021
Mar 22, 2021$0.15259Mar 31, 2021
Dec 21, 2020$0.13052Dec 31, 2020
Sep 21, 2020$0.11658Sep 30, 2020
Jun 22, 2020$0.15557Jun 30, 2020
Full Dividend History

News

Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?

Sector ETF report for PJP

4 hours ago - Zacks Investment Research

Blue-Chip Pharmaceuticals Stocks Contend With Political Headwinds

The Invesco Dynamic Pharmaceuticals ETF (NYSEArca: PJP) is off 3.66% month-to-date, and the source of that lethargy is easy to spot: The drug price reform debate is once again gaining momentum, promptin...

1 month ago - ETF Trends

Looking for Healthier Healthcare Stocks?

The healthcare sector is getting its groove back, as a variety of exchange traded funds dedicated to the group are printing or residing near new highs. The Invesco Dynamic Pharmaceuticals ETF (NYSEArca:...

2 months ago - ETF Trends

Pharma ETFs Gain on Q2 Earnings

Many industry bigwigs reported solid results with some beating on earnings or revenues or both.

Other symbols:FTXHIHEPPHXPH
2 months ago - Zacks Investment Research

Pharma & Healthcare ETFs at a One-Year High: Here's Why

Upbeat earnings, COVID-19-related sales, compelling valuation and lucrative dividend prospects are boosting pharma and healthcare ETFs.

2 months ago - Zacks Investment Research

Pharma ETFs in Focus Post Q1 Earnings

The slew of Q1 results have led to mixed trading in pharma ETFs over the past month.

Other symbols:FTXHIHEPPHXPH
5 months ago - Zacks Investment Research

Pharma ETFs in Focus Post Q4 Earnings

Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.

Other symbols:FTXHIHEPPHXPH
8 months ago - Zacks Investment Research

ETFs to Watch Ahead of Georgia Senate Runoff

Stocks came crashing on the first day of the New Year in apprehension of the outcome of the Georgia run-off elections.

9 months ago - Zacks Investment Research

ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion

AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.

Other symbols:BBHFBTPBEPPH
10 months ago - Zacks Investment Research

3 Reasons to Bet on Healthcare ETFs

The broader medical sector should be in the spotlight now on hopes of a coronavirus vaccine and the likelihood of a divided congress.

Other symbols:FTXHPPHPSCHXHSXPH
11 months ago - Zacks Investment Research

Vaccine Hopes & Divided Government: Sector ETFs to Win

News that a Pfizer and BioNTech vaccine candidate was more than 90% effective in avoiding COVID-19 in its clinical trial has instilled more optimism in the markets.

Other symbols:IHFJETSKREROOFRYE
11 months ago - Zacks Investment Research

ETF Areas to Win/Lose With Biden on the Verge of Victory

Though the counting process for the U.S. election outcome is still on, the prospect of a Joe Biden presidency marked by a divided Congress is rife.

11 months ago - Zacks Investment Research

Here's Why Healthcare ETFs Are Rallying Post Elections

Easing worries regarding major policy changes are driving the relief rally in the healthcare and biotech spaces in the post-election period.

Other symbols:IBBPPHVHTXBIXLV
11 months ago - Zacks Investment Research

Wining & Losing Sector ETFs Post Election Day

Chances of a dividend congress caused a superb rally in Wall Street the day after election.

11 months ago - Zacks Investment Research

Q3 Earnings Fail to Impress Pharma ETFs

The slew of Q3 results have led to mixed trading in pharma ETFs over the past month.

Other symbols:FTXHIHEPPHXPH
11 months ago - Zacks Investment Research

Healthcare ETFs: Winners & Losers in the Light of U.S. Election

The coronavirus vaccine development effort has put the spotlight on the U.S. healthcare sector in recent months.

Other symbols:CNBSGNOMIHEIHFIHIXHE
1 year ago - Zacks Investment Research

Best Pharmaceutical ETFs for Q4 2020

The best pharmaceutical ETFs for Q4 2020 are KURE, XPH, and PJP.

Other symbols:KUREXPH
1 year ago - Investopedia

Pharma ETFs Soar on Robust Q2 Earnings

Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.

Other symbols:FTXHIHEPPHXPH
1 year ago - Zacks Investment Research

5 Sector ETFs Just Got Upgraded to Buy

Zacks recently issued quarterly rank updates for ETFs and these sector ETFs have been upgraded to Buy.

Other symbols:IYJIYZKBERTHVFHVOXXPH
1 year ago - Zacks Investment Research

4 Sector ETF Winners of Bull Market Look Resilient to Virus

These sector ETFs emerged winners in the 11-year old bull market and may survive despite the coronavirus scare.

1 year ago - Zacks Investment Research

Pharma ETFs Gain on Healthy Q4 Earnings

Strong results led to solid trading in pharma ETFs over the past week.

Other symbols:FTXHIHEPPHXPH
1 year ago - Zacks Investment Research

Pharma Sector Tops in October: Best ETFs & Stocks

Pharma sector wins in October, making these ETFs and stocks winners.

1 year ago - Zacks Investment Research

Pharma ETFs Set to Benefit Post Strong Q3 Earnings

Robust results led to solid trading in pharma ETFs in a month.

Other symbols:FTXHIHEPPHXPH
1 year ago - Zacks Investment Research

Amgen to Buy Celgene's Otezla: 5 ETF Drugs

Amgen agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash.

Other symbols:BBHIBBIEIHPBE
2 years ago - Zacks Investment Research

Pharma Q2 Earnings Growth Highest: Time to Buy ETFs?

Despite robust results, pharma ETFs have been trending downward in a month.

Other symbols:FTXHIHEPPHXPH
2 years ago - Zacks Investment Research